Ozagrel

Drug Profile

Ozagrel

Alternative Names: Cataclot; Domenan; KCT-0809; OKY 046; OXY-046 HCl; Vega; Xanbon

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Kissei Pharmaceutical; Ono Pharmaceutical
  • Developer Kissei Pharmaceutical; Teika Pharmaceutical
  • Class Antiasthmatics; Antihistamines; Antithrombotics; Methacrylates; Small molecules
  • Mechanism of Action Thromboxane A2 receptor antagonists; Thromboxane A2 synthase inhibitors; Thromboxane synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma; Cerebral vasospasm; Diabetic nephropathies; Intracranial thrombosis
  • Phase III Dry eyes
  • No development reported Cough; Glomerulonephritis; Hypertension in pregnancy; Myocardial infarction; Transplant rejection
  • Discontinued Cerebral infarction

Most Recent Events

  • 23 Jul 2015 Kissei Pharmaceutical initiates enrolment in phase III trial for dry eyes in Japan (NCT02503163)
  • 17 Jul 2015 Phase-III clinical trials in Dry eyes in Japan (Ophthalmic) before July 2015 (NCT02503189)
  • 17 Jul 2015 Kissei Pharmaceutical initiates enrolment in phase III extension trial for Dry eyes in Japan (NCT02503176)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top